Amferia establishes R&D operations at AstraZeneca’s BioVentureHub
Amferia, an innovative medtech company developing novel antimicrobial materials for medical devices, is now establishing operations in the BioVentureHub at AstraZeneca Gothenburg.
The move to AstraZeneca’s BioVentureHub will enable Amferia to develop its own R&D labs, as well as benefit from the valuable networking opportunities and expertise in the hub. The move also aligns well with Amferia’s long-term vision of growth and expansion within medtech and anti-infective devices in the fight against antibiotic resistance.
Magnus Björsne, CEO of AstraZeneca’s BioVentureHub − “We are very happy to welcome Amferia to the BioVentureHub. Antibiotic resistance continues to be a major problem affecting people all over the world. Anand, Saba and the Amferia team are developing an innovative approach to tackling infections. They will add complementary skills and new perspectives to the collaborative innovation environment in the BioVenturehub. We look forward to see them thrive and grow!”
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes.